The purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
2 Primary · 4 Secondary · Reporting Duration: 24 months
Experimental Treatment
24 Total Participants · 1 Treatment Group
Primary Treatment: CD123-Specific Adapter (SPRX002) and Universal CAR-Modified T Cell (ARC-T Cells) · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: